Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Zheng, Guoping ^a   Ge, Menghua ^a   Qiu, Guanguan ^a   Shu, Qiang ^b   Xu, Jianguo ^a,c  

^a Shaoxing Second Hospital   (China)

^b CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN INJURY; CELL FUNCTION; CELL THERAPY; HEART DISEASE; HUMAN; IMMUNOMODULATION; KIDNEY DISEASE; LUNG DISEASE; MACROPHAGE; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; MESENCHYMAL STROMA CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INJURY; SPINAL CORD INJURY; WOUND HEALING;

ANIMALIA;

EID: 84938097275     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/989473     Document Type: Review

References (109)

1. A. J. Friedenstein, R. K. Chailakhjan, and K. S. Lalykina, "The development of fibroblast colonies in monolayer cultures of Guinea-pig bone marrow and spleen cells, " Cell and Tissue Kinetics, vol. 3, no. 4, pp. 393-403, 1970.
2. A. I. Caplan, "Mesenchymal stem cells, " Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641-650, 1991.
3. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells, " Science, vol. 284, no. 5411, pp. 143-147, 1999.
4. M. D. Griffin, S. J. Elliman, E. Cahill, K. English, R. Ceredig, and T. Ritter, "Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots" Stem Cells, vol. 31, no. 10, pp. 2033-2041, 2013.
5. G. Maria Spaggiari and L. Moretta, "Cellular and molecular interactions of mesenchymal stem cells in innate immunity, " Immunology and Cell Biology, vol. 91, no. 1, pp. 27-31, 2013.
6. K. Le Blanc, F. Frassoni, L. Ball et al., "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study, " The Lancet, vol. 371, no. 9624, pp. 1579-1586, 2008.
7. R. Ciccocioppo, M. E. Bernardo, A. Sgarella et al., "Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease, " Gut, vol. 60, no. 6, pp. 788-798, 2011.
8. J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, " Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
9. K. Le Blanc, C. Götherström, O. Ringdén et al., "Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta, " Transplantation, vol. 79, no. 11, pp. 1607-1614, 2005.
10. G. Zheng, L. Huang, H. Tong et al., "Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study, " Respiratory Research, vol. 15, no. 1, article 39, 2014.
11. J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., "Embryonic stem cell lines derived from human blastocysts, " Science, vol. 282, no. 5391, pp. 1145-1147, 1998.
12. S. D. Schwartz, C. D. Regillo, B. L. Lam et al., "Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: Follow-up of two open-label phase 1/2 studies, " The Lancet, vol. 385, no. 9967, pp. 509-516, 2015.
13. M. Wernig, J.-P. Zhao, J. Pruszak et al., "Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5856-5861, 2008.
14. J. Hanna, M. Wernig, S. Markoulaki et al., "Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin, " Science, vol. 318, no. 5858, pp. 1920-1923, 2007.
15. K. Okita, T. Ichisaka, and S. Yamanaka, "Generation of germline-competent induced pluripotent stem cells, " Nature, vol. 448, no. 7151, pp. 313-317, 2007.
16. P. Cipriani, P. Ruscitti, P. di Benedetto et al., "Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies, " Cytotherapy, vol. 17, no. 7, pp. 832-849, 2015.
17. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses, " Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
18. M. D. Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, " Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
19. S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi, "Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells, " Blood, vol. 105, no. 7, pp. 2821-2827, 2005.
20. S. Ghannam, J. Pene, G. Moquet-Torcy, C. Jorgensen, and H. Yssel, "Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype, " The Journal of Immunology, vol. 185, pp. 302-312, 2010.
21. S. Asari, S. Itakura, K. Ferreri et al., "Mesenchymal stem cells suppress B-cell terminal differentiation, " Experimental Hematology, vol. 37, no. 5, pp. 604-615, 2009.
22. M. Rafei, J. Hsieh, S. Fortier et al., "Mesenchymal stromal cell derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction, " Blood, vol. 112, no. 13, pp. 4991-4998, 2008.
23. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2, " Blood, vol. 111, no. 3, pp. 1327-1333, 2008.
24. S. Beyth, Z. Borovsky, D. Mevorach et al., "Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness, " Blood, vol. 105, no. 5, pp. 2214-2219, 2005.
25. J. Kim and P. Hematti, "Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages, " ExperimentalHematology, vol. 37, no. 12, pp. 1445-1453, 2009.
26. M. Gazdic, V. Volarevic, N. Arsenijevic, and M. Stojkovic, "Mesenchymal stem cells: a friend or foe in immune-mediated diseases, " Stem Cell Reviews and Reports, vol. 11, no. 2, pp. 280-287, 2015.
27. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for CellularTherapy position statement, " Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
28. G. C. Kopen, D. J. Prockop, andD. G. Phinney, "Marrowstromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 19, pp. 10711-10716, 1999.
29. F. Ezquer, M. Ezquer, D. Contador, M. Ricca, V. Simon, and P. Conget, "The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment, " Stem Cells, vol. 30, no. 8, pp. 1664-1674, 2012.
30. F. Mosna, L. Sensebé, andM. Krampera, "Human bone marrow and adipose tissuemesenchymal stem cells: a user's guide, " Stem Cells and Development, vol. 19, no. 10, pp. 1449-1470, 2010.
31. O. K. Lee, T. K. Kuo, W.-M. Chen, K.-D. Lee, S.-L. Hsieh, and T.-H. Chen, "Isolation of multipotent mesenchymal stem cells from umbilical cord blood, " Blood, vol. 103, no. 5, pp. 1669-1675, 2004.
32. S. Kern, H. Eichler, J. Stoeve, H. Klüter, and K. Bieback, "Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue, " StemCells, vol. 24, no. 5, pp. 1294-1301, 2006.
33. R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, "A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype, " PLoS ONE, vol. 5, no. 4, Article ID e10088, 2010.
34. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, "HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells, " Experimental Hematology, vol. 31, no. 10, pp. 890-896, 2003.
35. K. Le Blanc, L. Tammik, B. Sundberg, S. E. Haynesworth, andO. Ringdén, "Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures andmitogenic responses independently of the major histocompatibility complex, " Scandinavian Journal of Immunology, vol. 57, no. 1, pp. 11-20, 2003.
36. K. McIntosh, S. Zvonic, S. Garrett et al., "Theimmunogenicity of human adipose-derived cells: temporal changes in vitro, " Stem Cells, vol. 24, no. 5, pp. 1246-1253, 2006.
37. C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, and P. D. Kessler, "Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart, " Circulation, vol. 105, no. 1, pp. 93-98, 2002.
38. H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei et al., "Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14022-14027, 2009.
39. A. Monsel, Y.-G. Zhu, S. Gennai, Q. Hao, J. Liu, and J. W. Lee, "Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells, " Anesthesiology, vol. 121, no. 5, pp. 1099-1121, 2014.
40. R. H. Lee, A. A. Pulin, M. J. Seo et al., "Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6, " Cell Stem Cell, vol. 5, no. 1, pp. 54-63, 2009.
41. M. B. Herrera, B. Bussolati, S. Bruno et al., "Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury, " Kidney International, vol. 72, no. 4, pp. 430-441, 2007.
42. F. Tögel, J. Isaac, Z. Hu, K. Weiss, and C. Westenfelder, "Renal SDF-1 signalsmobilization and homing ofCXCR4-positive cells to the kidney after ischemic injury, " Kidney International, vol. 67, no. 5, pp. 1772-1784, 2005.
43. C. Xinaris, M. Morigi, V. Benedetti et al., "A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion, " Cell Transplantation, vol. 22, no. 3, pp. 423-436, 2013.
44. S.-C. Hung, R. R. Pochampally, S.-C. Hsu et al., "Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo, " PLoS ONE, vol. 2, no. 5, article e416, 2007.
45. Z. Cheng, L. Ou, X. Zhou et al., "Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance, " Molecular Therapy, vol. 16, no. 3, pp. 571-579, 2008.
46. F. Tögel, Z. Hu, K. Weiss, J. Isaac, C. Lange, and C. Westenfelder, "Administered mesenchymal stemcells protect against ischemic acute renal failure through differentiation-independentmechanisms, " The American Journal of Physiology-Renal Physiology, vol. 289, no. 1, pp. F31-F42, 2005.
47. P. Burra, D. Arcidiacono, D. Bizzaro et al., "Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury, "BMC Gastroenterology, vol. 12, article 88, 2012.
48. J. Xu, C. R. Woods, A. L. Mora et al., "Prevention of endotoxininduced systemic response by bone marrow-derived mesenchymal stem cells in mice, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 293, no. 1, pp. L131-L141, 2007.
49. S. Y. Ahn, Y. S. Chang, D. K. Sung et al., "Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage, " Stroke, vol. 44, no. 2, pp. 497-504, 2013.
50. S. H. J. Mei, J. J. Haitsma, C. C. Dos Santos et al., "Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis, "American Journal of Respiratory and Critical CareMedicine, vol. 182, no. 8, pp. 1047-1057, 2010.
51. K. Le Blanc and D. Mougiakakos, "Multipotent mesenchymal stromal cells and the innate immune system, " Nature Reviews Immunology, vol. 12, no. 5, pp. 383-396, 2012.
52. W. Ge, J. Jiang, J. Arp, W. Liu, B. Garcia, andH. Wang, "Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression, " Transplantation, vol. 90, no. 12, pp. 1312-1320, 2010.
53. K. Németh, A. Leelahavanichkul, P. S. T. Yuen et al., "Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production, " Nature Medicine, vol. 15, no. 1, pp. 42-49, 2009.
54. K. Nemeth, A. Keane-Myers, J. M. Brown et al., "Bone marrow stromal cells use TGF-to suppress allergic responses in a mouse model of ragweed-induced asthma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 12, pp. 5652-5657, 2010.
55. L. A. Ortiz, M. DuTreil, C. Fattman et al., "Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 11002-11007, 2007.
56. S. Danchuk, J. H. Ylostalo, F. Hossain et al., "Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-induced protein 6, " Stem Cell Research and Therapy, vol. 2, no. 3, article 27, 2011.
57. K. Sato, K. Ozaki, I. Oh et al., "Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells, " Blood, vol. 109, no. 1, pp. 228-234, 2007.
58. K. Akiyama, C. Chen, D. Wang et al., "Mesenchymal-stemcell-induced immunoregulation involves FAS-ligand-/FASmediated T cell apoptosis, " Cell Stem Cell, vol. 10, no. 5, pp. 544-555, 2012.
59. Y.-P. Li, S. Paczesny, E. Lauret et al., "Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway, " Journal of Immunology, vol. 180, no. 3, pp. 1598-1608, 2008.
60. M. Krampera, S. Glennie, J. Dyson et al., "Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, " Blood, vol. 101, no. 9, pp. 3722-3729, 2003.
61. R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Daübener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenasemediated tryptophan degradation, " Blood, vol. 103, no. 12, pp. 4619-4621, 2004.
62. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon-in the immunomodulatory activity of human bone marrow mesenchymal stem cells, " Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
63. M. M. Duffy, J. Pindjakova, S. A. Hanley et al., "Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor, " European Journal of Immunology, vol. 41, no. 10, pp. 2840-2851, 2011.
64. B. del Papa, P. Sportoletti, D. Cecchini et al., "Notch1modulates mesenchymal stem cells mediated regulatory T-cell induction, " European Journal of Immunology, vol. 43, no. 1, pp. 182-187, 2013.
65. Z. Selmani, A. Naji, I. Zidi et al., "Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte andnatural killer functionand to induce CD4+CD25highFOXP3+ regulatory T cells, " Stem Cells, vol. 26, no. 1, pp. 212-222, 2008.
66. K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon, "Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25forkhead box P3+ regulatory T cells, " Clinical & Experimental Immunology, vol. 156, no. 1, pp. 149-160, 2009.
67. H. Kavanagh and B. P. Mahon, "Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells, " Allergy, vol. 66, no. 4, pp. 523-531, 2011.
68. M. Li, X. Sun, X. Kuang, Y. Liao, H. Li, and D. Luo, "Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-beta, " Clinical and Experimental Immunology, vol. 178, no. 3, pp. 516-524, 2014.
69. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe, "Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells, " The Journal of Immunology, vol. 177, no. 4, pp. 2080-2087, 2006.
70. R. Ramasamy, H. Fazekasova, E. W.-F. Lam, I. Soeiro, G. Lombardi, and F. Dazzi, "Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle, " Transplantation, vol. 83, no. 1, pp. 71-76, 2007.
71. X.-X. Jiang, Y. Zhang, B. Liu et al., "Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells, " Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
72. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, "Interactions between human mesenchymal stem cells and natural killer cells, " Stem Cells, vol. 24, no. 1, pp. 74-85, 2006.
73. I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, "Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells, " Transplantation, vol. 76, no. 8, pp. 1208-1213, 2003.
74. G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation, " Blood, vol. 107, no. 4, pp. 1484-1490, 2006.
75. M. Giuliani, A. Bennaceur-Griscelli, A. Nanbakhsh et al., "TLR ligands stimulation protects MSC from NK killing, " Stem Cells, vol. 32, no. 1, pp. 290-300, 2014.
76. E. Muraille, O. Leo, and M. Moser, "Th1/Th2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escapemechanism" Frontiers in Immunology, vol. 5, article 603, 2014.
77. A. Mantovani, S. K. Biswas, M. R. Galdiero, A. Sica, and M. Locati, "Macrophage plasticity and polarization in tissue repair and remodelling, " The Journal of Pathology, vol. 229, no. 2, pp. 176-185, 2013.
78. M. Stein, S. Keshav, N. Harris, and S. Gordon, "Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation, " Journal of ExperimentalMedicine, vol. 176, no. 1, pp. 287-292, 1992.
79. S. K. Biswas and A. Mantovani, "Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, " Nature Immunology, vol. 11, no. 10, pp. 889-896, 2010.
80. M. Peled and E. A. Fisher, "Dynamic aspects of macrophage polarization during atherosclerosis progression and regression, " Frontiers in Immunology, vol. 5, article 579, 2014.
81. R. Parsa, P. Andresen, A. Gillett et al., "Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice, " Diabetes, vol. 61, no. 11, pp. 2881-2892, 2012.
82. P. J. Murray, J. E. Allen, S. K. Biswas et al., "Macrophage activation and polarization: nomenclature and experimental guidelines, " Immunity, vol. 41, no. 1, pp. 14-20, 2014.
83. M. M. Tiemessen, A. L. Jagger, H. G. Evans, M. J. C. van Herwijnen, S. John, and L. S. Taams, "CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19446-19451, 2007.
84. G. Raes, A. Beschin, G. H. Ghassabeh, and P. De Baetselier, "Alternatively activated macrophages in protozoan infections, " Current Opinion in Immunology, vol. 19, no. 4, pp. 454-459, 2007.
85. F. O. Martinez, A. Sica, A. Mantovani, and M. Locati, "Macrophage activation and polarization, " Frontiers in Bioscience, vol. 13, no. 2, pp. 453-461, 2008.
86. M. E. Shaul, G. Bennett, K. J. Strissel, A. S. Greenberg, and M. S. Obin, "Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice, " Diabetes, vol. 59, no. 5, pp. 1171-1181, 2010.
87. H. Choi, R. H. Lee, N. Bazhanov, J. Y. Oh, and D. J. Prockop, "Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages, " Blood, vol. 118, no. 2, pp. 330-338, 2011.
88. S. M. Melief, S. B. Geutskens, W. E. Fibbe, and H. Roelofs, "Multipotent stromal cells skew monocytes towards an antiinflammatory interleukin-10-producing phenotype by production of interleukin-6, " Haematologica, vol. 98, no. 6, pp. 888-895, 2013.
89. M. François, R. Romieu-Mourez, M. Li, and J. Galipeau, "Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation, " Molecular Therapy, vol. 20, no. 1, pp. 187-195, 2012.
90. S. M. Melief, E. Schrama, M. H. Brugman et al., "Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward antiinflammatory macrophages, " Stem Cells, vol. 31, no. 9, pp. 1980-1991, 2013.
91. Q.-Z. Zhang, W.-R. Su, S.-H. Shi et al., "Human gingiva-derived mesenchymal stem cells elicit polarization of M2 macrophages and enhance cutaneous wound healing, " Stem Cells, vol. 28, no. 10, pp. 1856-1868, 2010.
92. R. Shohara, A. Yamamoto, S. Takikawa et al., "Mesenchymal stromal cells of human umbilical cordWharton's jelly accelerate wound healing by paracrine mechanisms, " Cytotherapy, vol. 14, no. 10, pp. 1171-1181, 2012.
93. D. Jiang, Y. Qi, N. G. Walker et al., "The effect of adipose tissue derivedMSCs delivered by a chemically defined carrier on fullthickness cutaneous wound healing, " Biomaterials, vol. 34, no. 10, pp. 2501-2515, 2013.
94. S. H. Mei, S. D. McCarter, Y. Deng, C. H. Parker, W. C. Liles, and D. J. Stewart, "Prevention of LPS-induced acute lung injury in mice bymesenchymal stem cells overexpressing angiopoietin 1, " PLoS Medicine, vol. 4, no. 9, article e269, 2007.
95. L. Ionescu, R. N. Byrne, T. van Haaften et al., "Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 11, pp. L967-L977, 2012.
96. T. Maron-Gutierrez, J. D. Silva, K. D. Asensi et al., "Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice, " Critical Care Medicine, vol. 41, no. 11, pp. e319-e333, 2013.
97. M. A. Antunes, S. C. Abreu, F. F. Cruz et al., "Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema, " Respiratory Research, vol. 15, no. 1, article 118, 2014.
98. V. Dayan, G. Yannarelli, F. Billia et al., "Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction, " Basic Research in Cardiology, vol. 106, no. 6, pp. 1299-1310, 2011.
99. S. Ishikane, H. Hosoda, K. Yamahara et al., "Allogeneic transplantation of fetal membrane-derived mesenchymal stem cell sheets increases neovascularization and improves cardiac function aftermyocardial infarction in rats, " Transplantation, vol. 96, no. 8, pp. 697-706, 2013.
100. T. Ben-Mordechai, R. Holbova, N. Landa-Rouben et al., "Macrophage subpopulations are essential for infarct repair with and without stem cell therapy, " Journal of the American College of Cardiology, vol. 62, no. 20, pp. 1890-1901, 2013.
101. S. Adutler-Lieber, T. Ben-Mordechai, N. Naftali-Shani et al., "Human macrophage regulation via interaction with cardiac adipose tissue-derived mesenchymal stromal cells, " Journal of Cardiovascular Pharmacology andTherapeutics, vol. 18, no. 1, pp. 78-86, 2013.
102. W. Li, Q. Zhang, M. Wang et al., "Macrophages are involved in the protective role of human umbilical cord-derived stromal cells in renal ischemia-reperfusion injury, " Stem Cell Research, vol. 10, no. 3, pp. 405-416, 2013.
103. M. M. Duffy, B. A. McNicholas, D. A. Monaghan et al., "Mesenchymal stem cells and a vitaminDreceptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney, " The American Journal of Physiology-Renal Physiology, vol. 307, no. 12, pp. F1412-F1426, 2014.
104. A. F. Wise, T. M. Williams, M. B. G. Kiewiet et al., "Humanmesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemiareperfusion injury, " The American Journal of Physiology-Renal Physiology, vol. 306, no. 10, pp. F1222-F1235, 2014.
105. Y. Geng, L. Zhang, B. Fu et al., "Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages, " StemCell Research andTherapy, vol. 5, no. 3, article 80, 2014.
106. H. Nakajima, K. Uchida, A. R. Guerrero et al., "Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury, " Journal of Neurotrauma, vol. 29, no. 8, pp. 1614-1625, 2012.
107. J. Barminko, J. H. Kim, S. Otsuka et al., "Encapsulated mesenchymal stromal cells for in vivo transplantation, " Biotechnology and Bioengineering, vol. 108, no. 11, pp. 2747-2758, 2011.
108. K. Matsubara, Y. Matsushita, K. Sakai et al., "Secreted ectodomain of sialic acid-binding Ig-like lectin-9 andmonocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity, " Journal of Neuroscience, vol. 35, no. 6, pp. 2452-2464, 2015.
109. E. R. Zanier, F. Pischiutta, L. Riganti et al., "Bone marrow mesenchymal stromal cells drive protectiveM2microglia polarization after brain trauma, " Neurotherapeutics, vol. 11, no. 3, pp. 679-695, 2014.